200 related articles for article (PubMed ID: 26921089)
1. In Vitro and In Vivo Evaluation of Targeted Sunitinib-Loaded Polymer Microbubbles Against Proliferation of Renal Cell Carcinoma.
Hu J; Zong Y; Li J; Zhou X; Zhang J; Zhu T; Jiao M; Su H; Bo B
J Ultrasound Med; 2016 Mar; 35(3):589-97. PubMed ID: 26921089
[TBL] [Abstract][Full Text] [Related]
2. Hispidulin potentiates the antitumor effect of sunitinib against human renal cell carcinoma in laboratory models.
Gao H; Jiang Q; Han Y; Peng J; Wang C
Cell Biochem Biophys; 2015 Mar; 71(2):757-64. PubMed ID: 25260394
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
4. Targeting renal cell carcinoma with gambogic acid in combination with sunitinib in vitro and in vivo.
Jiang XL; Zhang Y; Luo CL; Wu XH
Asian Pac J Cancer Prev; 2012; 13(12):6463-8. PubMed ID: 23464475
[TBL] [Abstract][Full Text] [Related]
5. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
Sakai I; Miyake H; Fujisawa M
BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.
Maita S; Yuasa T; Tsuchiya N; Mitobe Y; Narita S; Horikawa Y; Hatake K; Fukui I; Kimura S; Maekawa T; Habuchi T
Int J Cancer; 2012 Feb; 130(3):677-84. PubMed ID: 21387300
[TBL] [Abstract][Full Text] [Related]
7. The dual effect of ultrasound-targeted microbubble destruction in mediating recombinant adeno-associated virus delivery in renal cell carcinoma: transfection enhancement and tumor inhibition.
Li F; Jin L; Wang H; Wei F; Bai M; Shi Q; Du L
J Gene Med; 2014; 16(1-2):28-39. PubMed ID: 24464622
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
Miyazaki A; Miyake H; Fujisawa M
Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma.
Yu N; Fu S; Xu Z; Liu Y; Hao J; Zhang A; Wang B
Int J Cancer; 2016 Jan; 138(2):451-62. PubMed ID: 26239999
[TBL] [Abstract][Full Text] [Related]
10. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
12. Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC.
Oosterwijk-Wakka JC; de Weijert MC; Franssen GM; Leenders WP; van der Laak JA; Boerman OC; Mulders PF; Oosterwijk E
Neoplasia; 2015 Feb; 17(2):215-24. PubMed ID: 25748241
[TBL] [Abstract][Full Text] [Related]
13. Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy.
Jha BK; Dong B; Nguyen CT; Polyakova I; Silverman RH
Mol Ther; 2013 Sep; 21(9):1749-57. PubMed ID: 23732991
[TBL] [Abstract][Full Text] [Related]
14. Kidney cancer: Power couple: reovirus meets sunitinib.
Thoma C
Nat Rev Urol; 2016 Aug; 13(8):436. PubMed ID: 27296650
[No Abstract] [Full Text] [Related]
15. A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse.
Maitani Y; Saito H; Seishi Y; Iwase Y; Yamauchi T; Higashiyama K; Sugino T
J Drug Target; 2012 Dec; 20(10):873-82. PubMed ID: 23050928
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma.
Larkin J; Esser N; Calvo E; Tsuchihashi Z; Fiedler U; Graeser R; Kim D
Anticancer Res; 2012 Jul; 32(7):2399-406. PubMed ID: 22753696
[TBL] [Abstract][Full Text] [Related]
17. Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.
Lawson KA; Mostafa AA; Shi ZQ; Spurrell J; Chen W; Kawakami J; Gratton K; Thakur S; Morris DG
Clin Cancer Res; 2016 Dec; 22(23):5839-5850. PubMed ID: 27220962
[TBL] [Abstract][Full Text] [Related]
18. Effect of High-Intensity Focused Ultrasound on Drug Release from Doxorubicin-Loaded PEGylated Liposomes and Therapeutic Effect in Colorectal Cancer Murine Models.
Jeong HS; Hwang H; Oh PS; Kim EM; Lee TK; Kim M; Kim HS; Lim ST; Sohn MH; Jeong HJ
Ultrasound Med Biol; 2016 Apr; 42(4):947-55. PubMed ID: 26795498
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis.
Bousquet G; Varna M; Ferreira I; Wang L; Mongiat-Artus P; Leboeuf C; de Bazelaire C; Faivre S; Bertheau P; Raymond E; Germain S; Janin A
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1183-93. PubMed ID: 24061866
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
